Pure Autonomic Failure News and Research

RSS

Towards better diagnosis of neurodegenerative disorders: Skin biopsy for α-synuclein detection proves effective

The positivity rate of cutaneous phosphorylated alpha-synuclein protein (P-SYN) deposition among individuals with dementia.

26 Mar 2024

Skin biopsy test shows promise in diagnosing Parkinson's disease and synucleinopathies

In a paper published in the Journal of the American Medical Association (JAMA), neurologists at Beth Israel Deaconess Medical Center (BIDMC) showed that a simple skin biopsy test detects an abnormal form of alpha-synuclein, the pathological hallmark of Parkinson's disease and the subgroup of neurodegenerative disorders known as synucleinopathies, at high positivity rates.

20 Mar 2024

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

A recently discovered protein, alpha-synuclein, has become one of the most attractive targets for developing new drugs with the potential to slow down or arrest the progression of Parkinson's disease

20 Dec 2018

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Chelsea Therapeutics International, Ltd. announced that a new investigator-led phase II clinical study of Droxidopa, an oral synthetic precursor of norepinephrine, has been initiated in chronic fatigue syndrome (CFS).

20 Aug 2010

Drinking water could help people suffering from low blood pressure who faint while standing

Ordinary tap or bottled water could help people suffering from low blood pressure who faint while standing, claim researchers from Imperial College London and St Mary's Hospital.

1 Dec 2004

Neurologists have discovered a drug application smart enough to alleviate orthostatic hypotension

Mayo Clinic neurologists have discovered a drug application smart enough to alleviate orthostatic hypotension -- problems with sinking blood pressure when standing up from a sitting position -- without the unwanted effect of also causing patients' blood pressure to soar when lying down.

5 Oct 2004

Pure Autonomic Failure News and Research

Towards better diagnosis of neurodegenerative disorders: Skin biopsy for α-synuclein detection proves effective

Skin biopsy test shows promise in diagnosing Parkinson's disease and synucleinopathies

Experts in Parkinson's research propose roadmap for drug trials targeting alpha-synuclein

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics announces new investigator to conduct phase II clinical study of Droxidopa

Drinking water could help people suffering from low blood pressure who faint while standing

Neurologists have discovered a drug application smart enough to alleviate orthostatic hypotension

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News